Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation
- Conditions
- ESCCBiliary Tract CancerGastric CancerPancreas Cancer
- Interventions
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT06531291
- Locations
- 🇨🇳
Renji hospital, Shanghai, Shanghai, China
DRug-coAted Balloon Compared With cuttinG balloON in Treatment of Arteriovenous Fistula Stenosis
- Conditions
- Arteriovenous FistulaAngioplasty, BalloonHemodialysis Access Failure
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 180
- Registration Number
- NCT06527963
- Locations
- 🇨🇳
First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
🇨🇳Renji Hospital, Shanghai, Shanghai, China
Prospective Real-World Study of HAIC With Raltitrexed or 5-Fluorouracil for the Treatment of Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Drug: hepatic artery infusion chemotherapy
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 1115
- Registration Number
- NCT06519578
- Locations
- 🇨🇳
Deparment of Liver Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
🇨🇳Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Safety and Efficacy Study of Lenvatinib Combined With VIC-1911 for the Treatment of Advanced HCC
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT06519721
- Locations
- 🇨🇳
Deparment of Liver Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
A Study of Enhancing Drug Prophylaxis of Venous Thromboembolism in Chinese Colorectal Cancer Surgery
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 914
- Registration Number
- NCT06513481
Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1)
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT06511349
- Locations
- 🇨🇳
Deparment of Liver Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA)
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 143
- Registration Number
- NCT06510465
- Locations
- 🇨🇳
Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
🇨🇳Renji Hospital, Shanghai, China
OXiris for Abdominal SEptic Shock (OASES Study)
- Conditions
- Septic ShockBlood PurificationMulti Organ FailureAbdominal SepsisAKI - Acute Kidney Injury
- Interventions
- Device: CRRT filter
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 192
- Registration Number
- NCT06504316
- Locations
- 🇨🇳
Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
Effectiveness of Endoluminal Treatment of Autologous Arteriovenous Endovascular Fistula Failure
- Conditions
- Hemodialysis Access Failure
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 180
- Registration Number
- NCT06493292
- Locations
- 🇨🇳
First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
🇨🇳Renji Hospital, Shanghai, Shanghai, China
Evaluate the Safety and Efficacy of BGT007H Cell Therapy in Patients With Relapsed/Refractory Pancreatic Cancer
- Conditions
- Tumor Pancreas
- Interventions
- Drug: BGT007H Cell Injection
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT06478225
- Locations
- 🇨🇳
Renji hospital, Shanghai, Shanghai, China